Journal of Clinical Oncology
Articles in this Issue
Using geospatial visualization to inform mobile lung cancer screening in Maryland.
e20098 Background: Geographic disparities in access to healthcare services may contribute to low uptake of lung cancer scr...
[ <sup>212</sup> Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3–expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy.
TPS3176 Background: [ 212 Pb]Pb-MP0712 is a novel radiopharmaceutical comprising a...
Intensity of chemotherapy regimens for patients with Lynch syndrome and colorectal cancer.
10608 Background: Lynch syndrome (LS), associated with inherited pathogenic variants (PVs) in MLH1, MS...
ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
4007 Background: Anti-PD-1 antibodies combined with chemo are the standard 1L treatment for HER2-negative G/GEJ cancer. Pr...
<i>KMT2C</i> mutation to identify an immunotherapy-sensitive subset of gastrointestinal cancers: A large real-world analysis.
3565 Background: KMT2C (MLL3) encodes a histone methyltransferase involved in enhancer regulation and...
A methods-forward indirect comparison of IO-IO versus IO-VEGF as first-line therapy for unresectable hepatocellular carcinoma.
e16214 Background: Many immune-based regimens are approved for first-line unresectable hepatocellular carcinoma (uHCC), ye...
Revisiting the role of immune checkpoint inhibitor–based combination therapies in favorable risk metastatic renal cell carcinoma: An updated pairwise and network meta-analysis of long-term survival outcomes.
e16504 Background: The benefit of immune checkpoint inhibitor (ICI)–based combination therapy in IMDC favorable risk metas...
Financial toxicity in early-phase cancer clinical trials: A review of sponsor-supplied information at a large trials unit.
1526 Background: Financial toxicity (FT), the objective financial burden and resulting subjective distress experienced by...
Safety and efficacy of ST316, a first in class ß-catenin antagonist, in metastatic colorectal cancer (mCRC).
e15622 Background: Aberrant activation of the Wnt/ß-catenin pathway is a critical driver of tumor progression and immune e...
KRAS mutational landscape and immune microenvironment features in pancreatic cancer: Implications for targeted and combination therapeutic strategies.
e16406 Background: The poor prognosis of pancreatic cancer and its high prevalence of KRAS mutations have made KRAS altera...
Two decades of landscape change in the treatment of multiple myeloma.
e19571 Background: The treatment of newly diagnosed multiple myeloma (NDMM) has evolved rapidly over the past two decades....
Intensity-modulated proton therapy versus intensity-modulated photon radiotherapy for locally advanced HPV-positive oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis.
e18060 Background: Intensity-modulated proton therapy (IMPT) has been gaining popularity as a method of treating locally a...
Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.
TPS2666 Background: Interleukin-2 (IL-2) has antitumor activity through stimulation of proliferation and differentiation o...
Endocrine stress phenotypes as drivers of extreme inpatient severity and resource utilization without increased mortality in cancer hospitalizations: National Inpatient Sample, 2018–2022.
e23201 Background: Endocrine complications during cancer hospitalization may reflect acute physiologic stress rather than...
Comorbidities and concomitant medication use in patients with TKI-naive, advanced, or metastatic ALK-positive NSCLC.
e20737 Background: Recommended therapies for anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)...
Treatment modalities among long-term survivors of primary pulmonary NUT carcinoma: A systematic review and meta-analysis.
e20782 Background: Primary pulmonary NUT carcinoma (NC) is a rare, highly aggressive malignancy with a reported median ove...
Liraglutide may be associated with increased skin cancer risk: A propensity score-matched analysis.
e21504 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used for type 2 diabetes (T2DM) and obesity b...
Associations of race and obesity with mortality and cardiotoxicity in breast cancer.
e23304 Background: Racial disparities in mortality and cardiotoxicity among breast cancer patients remain insufficiently c...
Evolution of immune checkpoint inhibitor trials in oncology from 2011 to 2025: A cross-sectional study.
11048 Background: Immune checkpoint inhibitors (ICIs) have transformed the oncology therapeutic landscape since the first...
Long-term trends and demographic disparities in renal cell carcinoma mortality in the United States, 1968–2023.
e16541 Background: Accounting for 2% of cancer diagnoses and deaths globally, renal cell carcinoma (RCC) is regarded as th...
Impact of postsurgical circulating tumor DNA (ctDNA) dynamics on eligibility of colorectal cancer (CRC) patients for randomized ALTAIR trial: Implications for treat-on-molecular-recurrence (TOMR) trials.
3628 Background: Postsurgical ctDNA positivity is strongly associated with recurrence risk and is driving the development...
A network meta-analysis of efficacy and safety of neoadjuvant anti-HER2 treatments in HER2-positive early breast cancer.
e12636 Background: Neoadjuvant treatment options for HER2-positive early breast cancer are continuously evolving, includin...
Antibiotics and immune-related toxicity during pembrolizumab therapy in NSCLC: Real-world analysis.
e20637 Background: Antibiotic exposure around immune checkpoint inhibitor (ICI) therapy has consistently been associated w...
A phase I, multi-center study of KIVU-107, a novel PTK7-targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors.
TPS3158 Background: Protein tyrosine kinase 7 (PTK7) is a transmembrane pseudokinase involved in normal embryonic developm...
The investigator-initiated trial (IIT) of GO306 injection, a recombinant oncolytic vaccinia virus, in patients with advanced soft tissue sarcomas.
11564 Background: Oncolytic vaccinia viruses exert anti-tumor effects via direct lysis and systemic immunity induction. Ad...